1Ma X, Norsworthy K, Kundu N, et al. CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model[J]. Mol Cancer Tiler, 2009,8 (3) :490-498.
2Murakami T,Kawada K,Iwamoto M ,et al. The role of CXCR3 and CXCR4 in colorectal cancer metastasis[J]. Int J Cancer,2013,132 (2) :276-287.
3Utsumi T ,Suyama T ,mamura Y ,et al. The association of CXCR3 and re- nal cell carcinoma metastasis[J]. J Urol, 2014,192 (2) : 567-574.
4Patrick M,Main P. Metastasis :a question of life or death[J]. Nat Re Cancer, 2006,6 (9) : 449-458.
5Moser B ,Loetscher P. Lymphocyte traffic control by chemoklnes[J]. Nat Immunol, 2001,2 ( 2 ) : 123 - 128.
6Luster AD. Chemokines chemotactic cytokines that mediate inflam- mation[J]. N Engl J Med, 1998,338 (7) : 436-445.
7Vandercappellen J,Van Damme J, Struyf S. The role of CXC chemokines and their receptors in cancer[J]. Cancer Lett, 2008 , 267 (2) : 226-244.
8Singh R, Lillard JW Jr, Singh S. Chemokines :key players in cancer pro- gression and metastasis[J]. Front Biosci(Schol Ed) ,2011 (3) : 1569-1582.
9Billottet C, Quemener C, Bikfalvi A. CXCR3, a double-edged sword in tumor progression and angiogenesis[J]. Biochim Biophys Acta,2013, 1836(2) :287-295.
10Ehlert JE,Addison CA,Burdick MD,et al. Identification and partial characterization of a variant of human CXCR3 generated by posttranscri- ptional exon skipping[J]. J Immuno1,2004,173 (10) :6234-6240.
二级参考文献10
1Perlis N, Zlotta AR, Beyene J, et al. Immediate post-tran- surethral resection of bladder tumor intravesical chemo- therapy prevents non-muscle-invasive bladder cancer re- currences:an updated meta-analysis on 2548 patients and quality-o~evidence review[J]. Eur Urol, 2013,64(3) :421-430.
2Jawa RS, Quist E, Boyer CW, et al. Mesenteric ischemia- reperfusion injury up-regulates certain CC, CXC, and XC ehemokines and results in multi-organ injury in a time-de- pendent mannerEJ]. Eur Cytokine Netw, 2014,24 (4) : 148-156.
3Bernat V, Heinrieh MR, Baumeister P, et al. Synthesis and application of the first radioligand targeting the allosteric binding pocket of chemokine receptor CXCR3 [J ]. ChemMedChem,2012,7(8) ~ 1481-1489.
4Singh AK, Arya RK,Trivedi AK, et al. Chemokine recep- tor trio: CXCR3, CXCR4 and CXCR7 crosstalk via CX- CL11 and CXCL12 [J]. Cytokine Growth Factor Rev, 2013,24(1) ~ 41-49.
5Murakami T, Kawada K, Iwamoto M, et al. The role of CXCR3 and CXCR4 in colorectal cancer metastasis[J]. Int J Cancer,2013,132(2) :276-287.
6Bedognetti D, Spivey TL, Zhao Y, et al. CXCR3/CCR5 path- ways in metastatic melanoma patients treated with adoptive therapy and interleukin-2 [J]. Br J Cancer, 2013, 109 (9) : 2412-2423.
7Hilborn E, Sivik T, Fornander T, et al. C-X-C ligand I0 and C-X-C receptor 3 status can predict tamoxifen treat- ment response in breast cancer patients[J]. Breast Cancer Res Treat,2014,145(1) :73-82.
